SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Targeted TherapiesOctober 1, 2026

RAS alterations drove resistance in about one in ten oncogene-driven lung cancers progressing on targeted therapy

RAS alterations account for resistance to targeted therapy in roughly one in ten oncogene-driven lung cancers, according to a study of 590 patients published in Annals of Oncology, which also found that adding a RAS inhibitor to osimertinib was synergistic in patient-derived models of KRAS-mediated resistance.
Share

In brief

  • From 590 patients with oncogene-driven lung cancer assessed at resistance to targeted therapy, the authors estimate that RAS alterations mediate resistance in about 10% of cases.
  • Among 312 patients progressing on first-line osimertinib, 35 (11.2%) had a RAS alteration, with KRAS G12D in 10 and KRAS G12C in one.
  • In 148 patients with ALK-positive disease, RAS alterations were more common after lorlatinib than after second-generation ALK inhibitors (14.7% vs 5%, P=0.0444).
  • RAS alterations were found in 7% to 16% of MET-, ROS1- and RET-driven cancers progressing on targeted agents.
  • In two patient-derived models with KRAS G12D or G12R acquired on osimertinib, combining osimertinib with zoldonrasib or daraxonrasib was synergistic in vitro and in vivo.

Study at a glance

  • Cohort: 590 patients with oncogene-driven lung cancer at progression on targeted therapy
  • EGFR: 312 patients progressing on first-line osimertinib
  • ALK: 148 patients, after lorlatinib or second-generation ALK inhibitors
  • Other drivers: MET, ROS1 and RET, at progression on targeted agents
  • Testing: tissue and liquid biopsies
  • RAS alterations after osimertinib: 35 of 312 (11.2%); KRAS G12D n=10, KRAS G12C n=1
  • Preclinical models: two patient-derived models with acquired KRAS G12D and G12R, treated with osimertinib plus zoldonrasib or daraxonrasib
  • Not reported: patient numbers for the MET, ROS1 and RET groups, and any clinical outcome with a RAS inhibitor (in the abstract)

Newer inhibitors push resistance towards other pathways

The study starts from the observation that next-generation targeted therapies are particularly active against on-target resistance, which the authors argue favours the emergence of off-target mechanisms when patients eventually relapse.

Most patients with oncogene-driven lung cancer do relapse, despite the activity of these drugs. RAS inhibitors now in clinical development could, on the authors’ reading, have a role against resistance that runs through RAS, which is the question the study sets out to size and to test.

RAS alterations in 11.2% after first-line osimertinib, mostly KRAS G12D

Of the 312 patients with EGFR-mutant disease who progressed on first-line osimertinib, 35 carried a RAS alteration, and KRAS G12D accounted for ten of them against a single KRAS G12C mutation.

The authors report that tissue and liquid biopsies played a major complementary role in identifying resistance mechanisms in this group. The scarcity of G12C is relevant to treatment choice, because the approved KRAS inhibitors most used in lung cancer, sotorasib and adagrasib, target G12C.

In ALK-positive disease, more RAS resistance after lorlatinib

Among 148 patients with ALK-positive lung cancer, RAS alterations were present in 14.7% at resistance to the third-generation inhibitor lorlatinib, compared with 5% at resistance to second-generation ALK inhibitors (P=0.0444).

This fits the authors’ premise that a more potent on-target inhibitor leaves more room for off-target escape. The comparison is between patients who received different drugs, however, and the P value sits just under 0.05. Across MET-, ROS1- and RET-driven lung cancers at progression on targeted agents, RAS alterations were detected in 7% to 16% of cases.

Osimertinib plus a RAS inhibitor was synergistic in two patient-derived models

The investigators built the models from tumours that had acquired KRAS G12D or KRAS G12R at osimertinib progression, and tested osimertinib with the selective KRAS G12D inhibitor zoldonrasib or with the pan-RAS inhibitor daraxonrasib.

Both combinations showed marked synergistic activity in cell culture and in animal models. The evidence for the combinations is therefore preclinical and rests on two models.

A basis for clinical trials of RAS-directed combinations

The authors conclude that RAS alterations mediate resistance to targeted agents in about 10% of oncogene-driven lung cancers, and that rational combinations with the new RAS inhibitors are effective in preclinical models, providing the basis for their clinical investigation.

The distribution of alterations found here is relevant to how such trials are designed. After osimertinib, a G12D-selective agent would cover more of the patients in this series than a G12C inhibitor, and a pan-RAS inhibitor would cover alterations such as G12R that neither selective agent targets.

Sources

  1. Annals of Oncology. Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer (2026-08-01). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Biagio Ricciuti, Jordi Remon and David Planchard.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Sep 26 2025
ILCS 2025
Targeted Therapies

DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?

} 31 min

T. Newsom-DavisX. Le
Sep 26 2025
ILCS 2025
Targeted Therapies

Actionable Genomic Alterations – Including HER2 and MET

} 26 min

S. Saw
Sep 26 2025
ILCS 2025
Targeted Therapies

Targeting EGFR and ALK in NSCLC

} 26 min

T. John
Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
Biagio Ricciuti
Oct 04 2024
ILCS 2024
Targeted Therapies

Decoding Actionable Alterations: Insights from KRAS, HER2, and c-MET

} 25 min

B. Ricciuti
Roberto Ferrara
Oct 04 2024
ILCS 2024
Targeted Therapies

Rare But Actionable: How To Target for RET, METex14 and NTRK

} 20 min

R. Ferrara
Anne-Marie Dingemans
Oct 04 2024
ILCS 2024
Targeted Therapies

Current Options in Targeting EGFR and ALK Beyond Osimertinib and Alectinib

} 25 min

A. Dingemans
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
SCLC

Debate: which is the better choice in 1L ES-SCLC?

G. MountziosA. Dingemans
Nov 13 2026
ILCS 2026
SCLC

The emerging role of T-cell engagers and ADCs in SCLC

N. Frost
Articles
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 12 2026
RESEARCH
BiomarkersResectable NSCLCTargeted Therapies

MTAP loss seen in 17% of NSCLC by immunohistochemistry, with PRMT5 inhibitors active in TKI-resistant cells

Z. Piotrowska
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Oct 31 2026
RESEARCH
Advanced NSCLCTargeted Therapies

VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries

A. Cortellini
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 18 2026
RESEARCH
Advanced NSCLCTargeted Therapies

First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg

X. LeD. PlanchardM. Pérol
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 15 2026
NEWS
Resectable NSCLC

A papal diagnosis turns the world’s attention to its most diagnosed cancer

Oct 14 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue

N. Girard
Oct 08 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Amivantamab, lazertinib and bevacizumab gave a 33% response rate after osimertinib in AMAZE-lung

R. StahelM. PérolA. AddeoS. Peters
Alfredo Addeo
Oct 05 2026
RESEARCH
Advanced NSCLCTargeted Therapies

A JCO review sets PACC mutations and exon 20 insertions apart from classical EGFR mutations in NSCLC

A. AddeoX. Le
Nikolaj Frost
Oct 04 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

Checkpoint inhibitors were associated with longer survival in NSCLC after allogeneic stem cell transplantation

N. FrostM. ReckA. Cortellini
Oct 03 2026
RESEARCH
Advanced NSCLCResectable NSCLCTargeted Therapies

AI-extracted records describe stage I–III NSCLC care at four Spanish hospitals before immunotherapy

A. Calles
Oct 03 2026
RESEARCH
Advanced NSCLCTargeted Therapies

KRAS inhibitors in NSCLC: modest survival gains, inevitable resistance and combinations in early trials

V. Noronha
Oct 02 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Sutetinib produced responses in 71% of patients with uncommon EGFR mutations in a phase IIb trial

X. Le
Oct 01 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Uncommon EGFR exon 19 deletions were associated with shorter PFS on osimertinib in a 111-patient study

H. Horinouchi
Sep 25 2026
RESEARCH
Resectable NSCLCTargeted Therapies

Multi-omic profiling separated recurrence risk within pathological stage in resected EGFR-mutant lung adenocarcinoma

S. Saw
Portrait of Dr. Alexander Drilon
Sep 23 2026
CONGRESS
Advanced NSCLCTargeted Therapies

Zidesamtinib produced responses in 94% of ROS1 TKI-naive patients in ARROS-1

Sep 18 2026
INDUSTRY NEWS
Advanced NSCLCTargeted Therapies

Sevabertinib approved in the US for untreated HER2-mutant NSCLC

Sep 17 2026
CONGRESS
Resectable NSCLCTargeted Therapies

Adjuvant osimertinib reduced the risk of death by 47% at eight years in ADAURA